Treatments
Asian countries prioritise rare disease market access amid stark disparities
Ahead of APEC’s "Rare disease vision 2025" deadline, Asian countries are working at different speeds towards improving drug market access.
Tetra receives rare paediatric disease designation for FXS therapy
FDA accepts Takeda’s NDA resubmission for eosinophilic esophagitis therapy
Pfizer receives EC approval for LITFULO to treat severe alopecia areata
Orexo announces NDA submission to FDA for opioid overdose therapy
Astellas to build drug production facility in Ireland
